# Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease

> **NCT02641054** · PHASE2 · COMPLETED · sponsor: **CleveXel Pharma** · enrollment: 21 (actual)

## Conditions studied

- Idiopathic Parkinson Disease

## Interventions

- **DRUG:** CVXL-0107
- **DRUG:** Placebo
- **DRUG:** Levodopa

## Key facts

- **NCT ID:** NCT02641054
- **Lead sponsor:** CleveXel Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2017-06
- **Final completion:** 2017-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02641054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02641054, "Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02641054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*